Connect your AI

AARD AARD Net Investment in Lease

Net Investment in Lease at other companies

Rhythm Pharmaceuticals, Inc.RYTM

——

Aquestive Therapeutics, Inc.AQST

——

Viking TherapeuticsVKTX

——

ArvinasARVN

——

Protagonist TherapeuticsPTGX

——

Other financials

Income statement

Revenue-—

Operating income-$22.5M-115%

Net income-$21.6M-132%

EPS (diluted)-$0.99-39.4%

Balance sheet

Cash & equivalents$62.4M+136%

Total debt$336.0K-53.7%

Total equity$87.0M-42.3%

Total assets$98.6M-37.2%

Cash flow

Operating cash flow-$18.9M-65.7%

CapEx--100%

Free cash flow-$16.8M-117%

Valuation

Market cap$124.35M-58.6%

Enterprise value$62.25M-77.4%

Returns & leverage

Return on equity-58.8%—

Debt / equity0×0.0×

Current ratio8.1×-17.8×

Where this comes from

Reported directly by AARD in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: AARD’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about AARD's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is AARD's net investment in lease?: AARD (AARD) reported net investment in lease of $269K in Q1 2026.
How has AARD's net investment in lease changed year-over-year?: AARD's net investment in lease decreased by 57.2% year-over-year, from $628K to $269K.